Skip to main content

Advertisement

Table 2 Univariate analysis of possible prognostic factors and impact of first-line treatment modalities on PFS and OS

From: Analysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement

  PFS OS
HR [95% CI] P HR [95% CI] P
Age >60 years 2.85 [1.19, 6.86] 0.02 3.70 [1.22, 11.22] 0.02
Ann Arbor stage IIIE-IVE 4.92 [1.67, 14.52] 0.004 6.41 [1.43, 28.59] 0.01
LDH above normal 2.18 [0.89, 5.33] 0.09 2.29 [0.72, 7.26] 0.16
ECOG >1 3.34 [1.45, 7.70] 0.005 4.27 [1.54, 11.83] 0.005
No. of extranodal sites
  > 1   > 2   > 3 1.24 [0.50, 3.05] 2.64 [1.09, 6.36] 5.69 [1.99, 16.31] 0.64 0.03 0.001 1.11 [0.38, 3.27] 2.56 [0.87, 7.51] 5.91 [1.79, 19.53] 0.85 0.09 0.004
hypercalcemia 4.69 [1.57, 14.03] 0.006 7.52 [2.34, 24.12] 0.0007
AP above normal 0.88 [0.35, 2.16] 0.77 0.71 [0.22, 2.24] 0.56
Multifocal bone lesions 1.10 [0.48, 2.52] 0.83 1.23 [0.44, 3.46] 0.69
Rituximab 0.76 [0.29, 2.00] 0.58 1.12 [0.30, 4.14] 0.87
Intensified chemotherapy 0.44 [0.16, 1.18] 0.10 0.44 [0.12, 1.57] 0.21
Radiotherapy 0.55 [0.20, 1.47] 0.23 0.09 [0.01, 0.72] 0.02
  1. Abbreviations: HR indicates hazard ratio, CI confidence interval, and P p-value